Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.370
-0.040 (-2.84%)
At close: Oct 27, 2025, 4:00 PM EDT
1.390
+0.020 (1.46%)
After-hours: Oct 27, 2025, 7:03 PM EDT
Equillium Revenue
Equillium had revenue of $16.55M in the twelve months ending June 30, 2025, down -61.16% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$16.55M
Revenue Growth
-61.16%
P/S Ratio
2.94
Revenue / Employee
$472,943
Employees
35
Market Cap
81.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.10M | 5.01M | 13.89% |
| Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
| Dec 31, 2022 | 15.76M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EQ News
- 5 days ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire
- 21 days ago - Equillium Announces Leadership and Corporate Updates - GlobeNewsWire
- 4 weeks ago - NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor - GlobeNewsWire
- 7 weeks ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Equillium to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
- 2 months ago - Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC - Seeking Alpha
- 2 months ago - Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic - Business Wire
- 3 months ago - Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy - Business Wire